7.48
CNS Pharmaceuticals, Inc.
Metrics score locked — part of Premium
FY21
FY22
FY23
FY24
FY25
FY21 – FY25
Assets
(positive)
Change from FY21 to FY25
millions USD
FY21:
FY22:
12.6
FY23:
1.59
FY24:
8.66
FY25:
8.10
(positive)
Change from FY21 to FY25
millions USD
FY21:
1.28
FY22:
0.49
FY23:
0.11
FY24:
0.04
FY25:
0.52
Total assets
Change from FY21 to FY25
millions USD
FY21:
8.76
FY22:
13.1
FY23:
1.70
FY24:
8.70
FY25:
8.62
Liabilities & Equity
(negative)
Change from FY21 to FY25
millions USD
FY21:
2.59
FY22:
4.92
FY23:
6.13
FY24:
2.52
FY25:
4.10
(negative)
millions USD
FY21:
0
FY22:
0
FY23:
0
FY24:
0
FY25:
0
(positive)
Change from FY21 to FY25
millions USD
FY21:
6.16
FY22:
8.13
FY23:
−4.43
FY24:
6.18
FY25:
4.52
Total liabilities & equity
Change from FY21 to FY25
millions USD
FY21:
8.76
FY22:
13.1
FY23:
1.70
FY24:
8.70
FY25:
8.62
All amounts in millions USD